Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination

Clin Appl Thromb Hemost. 2021 Jan-Dec:27:10760296211040110. doi: 10.1177/10760296211040110.

Abstract

Since the outbreak of Covid-19 in December, 2019, scientists worldwide have been committed to developing COVID-19 vaccines. Only when most people have immunity to SARS-CoV-2, COVID-19 can reduce even wholly overcome. So far, nine kinds of COVID-19 vaccines have passed the phase III clinical trials and have approved for use. At the same time, adverse reactions after COVID-19 vaccination have also reported. This paper focuses on the adverse effects of thrombosis and thrombocytopenia caused by the COVID-19 vaccine, especially the adenovirus-vector vaccine from AstraZeneca and Pfizer, and discusses its mechanism and possible countermeasures.

Keywords: COVID-19; SARS-CoV-2; adenovirus-vectored vaccine; adverse effect; thrombocytopenia; thrombosis.

Publication types

  • Review

MeSH terms

  • Adenoviridae / genetics*
  • Antibodies / blood
  • COVID-19 Vaccines / adverse effects*
  • COVID-19 Vaccines / genetics
  • COVID-19 Vaccines / immunology
  • ChAdOx1 nCoV-19
  • Genetic Vectors*
  • Humans
  • Platelet Factor 4 / immunology
  • Risk Assessment
  • Risk Factors
  • Thrombocytopenia / blood
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / immunology
  • Thrombosis / blood
  • Thrombosis / chemically induced*
  • Thrombosis / immunology
  • Vaccination / adverse effects*

Substances

  • Antibodies
  • COVID-19 Vaccines
  • PF4 protein, human
  • Platelet Factor 4
  • ChAdOx1 nCoV-19